Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
-
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
-
AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit
-
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
-
TruGolf Reports First Quarter 2026 Results
-
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR
-
Canadian Net REIT Announces 2026 First-Quarter Results and a Distribution Increase
-
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
-
Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
-
NVIDIA Announces Upcoming Events for Financial Community
-
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
-
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
-
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
-
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
-
Navient declares second quarter common stock dividend
-
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2
-
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
-
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
-
Legend Biotech Announces Presentations at ASCO 2026
-
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
-
Banco Comercial Português, S.A., announces the commencement of duties of the Board of Directors for the 2026-2029 four-year term
-
Banqup delivers 40,3% y/y growth in subscription revenue in Q1 2026
-
The Math Underlying the Success of Tort Reforms – Florida Property Insurance and Beyond
-
AMSC to Report Fourth Quarter and Fiscal Year 2025 Financial Results on May 27, 2026
-
CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman
-
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
-
Hub Group Declares Quarterly Dividend
-
Viral Reddit Sensation My Gums Are Bleeding Expands into Graphic Novel, Merchandise Line, and Franchise Launch
-
THRiYV Expands Nootropic Energy Line, Delivering a Cleaner Alternative to Nicotine Pouches & Energy Drinks
-
THRiYV Expands Nootropic Energy Line, Delivering a Cleaner Alternative to Nicotine Pouches & Energy Drinks
-
Kadant Authorizes Share Repurchase
-
Kadant Declares Cash Dividend
-
Mental Health Care in Utah Gets Major Boost with New Behavioral Health Center at Intermountain Health Alta View Hospital
-
Abcourt announces its financial results for the quarter ended March 31, 2026
-
Hub Group Receives Expected Deficiency Notice from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
-
ROHM Launches ESD Protection Diodes for High-Speed Interfaces Exceeding 10 Gbps
-
OFA Group Transitions to U.S. Domestic Issuer Status; Reaffirms United States as the Center of Its Growth Strategy
-
Genco Shipping & Trading Limited Files Investor Presentation and Urges Shareholders to Vote for the Company’s Highly Qualified Nominees and Reject Diana’s Inadequate Tender Offer
-
Announcement from Eimskip: Agreement between SA (on behalf of Eimskip) and the Seafarers Union of Iceland (on behalf of harbor employees)
-
Genco Shipping & Trading Limited Files Investor Presentation and Urges Shareholders to Vote for the Company’s Highly Qualified Nominees and Reject Diana’s Inadequate Tender Offer
-
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
-
Meritage Homes Announces Quarterly Cash Dividend
-
Americold Realty Trust, Inc. Declares Second Quarter 2026 Dividend
-
X-energy to Report First Quarter 2026 Results on June 4, 2026
-
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
-
VALHI ANNOUNCES QUARTERLY CASH DIVIDEND AND RESULTS OF ANNUAL STOCKHOLDER MEETING
-
Quanex Building Products Announces Second Quarter 2026 Earnings Release and Conference Call Schedule
-
Laureate Education Announces Election of Julian Coulter to Board of Directors
-
CULTURED VINE AND FREEMARK ABBEY ANNOUNCE JUDGMENT OF NAPA 2026: A ONCE-IN-A-GENERATION BLIND TASTING EVENT TO HONOR THE 50TH ANNIVERSARY OF THE HISTORIC JUDGMENT OF PARIS
-
Chemung Financial Corporation Announces Quarterly Dividend
